Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models-Reference-Cited by-同舟云学术

Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models

Published:2021-04-30 Issue:5 Volume:5 Page:e565
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Basu Titiksha,Bertrand Hannah,Karantzelis Nikolaos,Gründer Albert,Pahl Heike L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference31 articles.

1. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.;Ciboddo;Hematology Am Soc Hematol Educ Program,2018

2. Polycythemia vera.;Spivak;Curr Treat Options Oncol,2018

3. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.;Mughal;Leuk Res,2018

4. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.;Vannucchi;Ann Hematol,2017

5. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.;Deininger;Blood,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Candidate molecular targets uncovered in mouse lifespan extension studies;Expert Opinion on Therapeutic Targets;2024-04-30

2. Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm;Blood;2022-12-01

3. Epo-IGF1R crosstalk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm;2022-06-29